Venous Thromboses
Conditions
Brief summary
Part 1 - Evaluate the real-world implementation of extended prophylaxis with betrixaban in the acutely ill hospitalized medical population Part 2 - Describe patterns of Venous thromboembolism (VTE) prophylaxis in acutely ill medical patients who qualify for extended VTE prophylaxis
Interventions
None listed
Sponsors
Portola Pharmaceuticals
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
-Part 1 - 1. Hospitalized acutely ill medical patient 2. Patient prescribed betrixaban 3. Signed informed consent Part 2 - 1. Hospitalized acutely ill medical patient 2. Patient prescribed betrixaban OR must satisfy criteria a and b: 1. Moderately or severely restricted immobility: patient restricted to bed for at least 24 hours (severe) or restricted to bed for at least 12 hours (moderate) during their hospitalization 2. At least One additional risk factor: Age \> 70 years D-dimer \> 2x institutional Upper Limit of Normal (ULN) Obesity: Body mass index (BMI) \> 30 kg/m2) History of pulmonary embolism (PE) or deep venous thrombosis (DVT) Active cancer (diagnosed, treated, or progressing in the past 6 months) History of thrombophilia Recent trauma or surgery (within 30 days prior to admission) Ongoing hormonal treatment ICU stay 3. Signed informed consent
Exclusion criteria
* Part 1 - 1. High bleeding risk - any of the following: 1. Patient on dialysis 2. Low platelet count (\<50 per 109/L) 3. Known bleeding disorder (congenital or acquired) 4. Liver disease prohibitive to anticoagulation 5. Bleeding within last 30 days 6. Use of Dual Anti-Platelet Therapy (DAPT) Part 2 1. Patients who are on another oral anticoagulant (OAC) for any reason at the time of hospitalization and will remain on it 2. Condition requiring use of OAC at admission, other than VTE prophylaxis (eg, acute VTE at admission) 3. High bleeding risk any of the following: 1. Patient on dialysis 2. Low platelet count (\<50 per 109/L) 3. Known bleeding disorder (congenital or acquired) 4. Liver disease prohibitive to anticoagulation 5. Bleeding within last 30 days 6. Use of Dual Anti-Platelet Therapy (DAPT)
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Thrombotic Events at 45 days: VTE, MI, Stroke, Transient ischemic attack (TIA) | 45 days | Thrombotic Events at 45 days: VTE, MI, Stroke, TIA |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Bleeding rates at 45 days | 45 days | Bleeding rates at 45 days |
Countries
United States
Outcome results
None listed